Entropy Neurodynamics Limited
ENP
Clasificación en acciones
#26196
Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical... Entropy Neurodynamics Limited operates as a clinical-stage pharmaceutical company, dedicated to pioneering novel formulations for psilocin administration. These formulations are intended for use alongside psychotherapy, aiming to tackle medical conditions with pressing unmet needs across Australia, Canada, Switzerland, and the United States. The firm's flagship development is TRP-8803, an intravenously infused psilocin formulation that has successfully concluded Phase 2 clinical trials. These trials investigated its potential to treat binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. Additionally, the company is advancing TRP-8802, a synthetic, orally administered psilocybin compound. TRP-8802 is currently undergoing Phase 2a clinical trials for binge eating and is in Phase 2 clinical development for fibromyalgia and irritable bowel syndrome. Established in 2019 and headquartered in Camberwell, Australia, the company adopted its current name, Entropy Neurodynamics Limited, in November 2025, having previously operated as Tryptamine Therapeutics Limited.
Precio por acción
$0.02468497
Última sincronización: 2026-07-30
Capitalización bursátil
$40.28M
Cambio (1 día)
0.00%
Cambio (1 año)
-56.08%
País
AU
Comercio Entropy Neurodynamics Limited (ENP)
Categoría
Healthcare
Capitalización de mercado de Entropy Neurodynamics Limited(ENP)
Capitalización bursátil: $40.28M
A fecha de October 2026, Entropy Neurodynamics Limited tiene una capitalización de mercado de $40.28M. Esto convierte a Entropy Neurodynamics Limited en la 26196th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Entropy Neurodynamics Limited desde 2021 hasta 2026
ENP en comparación con los más populares 5 títulos stocks
